ARTICLE | Company News
uniQure restructuring news
November 18, 2016 9:19 PM UTC
uniQure said it will reduce headcount by 50-60 (20-25%) to about 190 by YE17 to focus on key pipeline projects. The company expects the job cuts will save €5-€6 million ($5.4-$6.4 million) annually, while reprioritizing the pipeline will reduce expenses by €11-€15 million ($11.8-$16.1 million) over two years.
Top pipeline priorities will be AMT-060 and AMT-130. AMT-060, an adeno-associated viral serotype 5 (AAV5) vector carrying the Factor IX gene, is in Phase I/II testing to treat hemophilia B. AMT-130, an AAV5 vector carrying cassette-optimized synthetic microRNAs to silence the Huntingtin (HTT) gene, is in preclinical testing to treat Huntington's disease...